Choline Alfoscerate
drug drugOn this page
Also known as Alfoscerate de cholineAlfoscerato de colinaAlpha-glycerylphosphorylcholineCholine alphoscerateGliatilinGlycerophosphocholineL-.alpha.-glycerylphosphorylcholineL-alpha-glycerylphosphorylcholine
Summary
Choline Alfoscerate (CHEMBL6067974) is a phase-3 clinical-stage unknown (ATC N07AX02); indicated across 2 conditions including type 2 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: N07AX02
- Indications: 2 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6067974 |
| Name | Choline Alfoscerate |
| Type | Unknown |
| Max phase | 3 |
| ATC | N07AX02 |
Also known as: Alfoscerate de choline, Alfoscerato de colina, Alpha-glycerylphosphorylcholine, Choline alfoscerate, Choline alphoscerate, Gliatilin, Glycerophosphocholine, L-.alpha.-glycerylphosphorylcholine, L-alpha-glycerylphosphorylcholine, CHOLINE ALFOSCERATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 5 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01363648 | PHASE4 | COMPLETED | The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia |
| NCT02648906 | PHASE4 | UNKNOWN | A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients |
| NCT05041790 | PHASE4 | UNKNOWN | A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment |
| NCT05050604 | PHASE4 | UNKNOWN | A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients |
| NCT05383183 | PHASE4 | UNKNOWN | Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer’s Disease |
| NCT03249259 | PHASE3 | COMPLETED | The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes |
| NCT03228498 | PHASE2 | COMPLETED | Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment |
| NCT02395926 | PHASE1 | COMPLETED | To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers |
| NCT05257902 | Not specified | UNKNOWN | Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: type 2 diabetes mellitus